help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tagami, T.
Right arrow Articles by Jameson, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tagami, T.
Right arrow Articles by Jameson, J. L.
Endocrinology Vol. 139, No. 5 2535-2544
Copyright © 1998 by The Endocrine Society

ARTICLES

The Thyroid Hormone Receptor Variant {alpha}2 Is a Weak Antagonist because It Is Deficient in Interactions with Nuclear Receptor Corepressors1

Tetsuya Tagami2, Peter Kopp2,3, Wade Johnson, Onur K. Arseven and J. Larry Jameson

Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Medical School, Chicago, Illinois 60611

Address all correspondence and requests for reprints to: J. Larry Jameson, M.D., Ph.D., Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Medical School, Tarry 15–709, 303 East Chicago Avenue, Chicago, Illinois 60611. E-mail: ljameson{at}nwu.edu

The thyroid hormone receptor splice variant, {alpha}2, is unable to bind thyroid hormone (T3) and has been proposed to function as an endogenous inhibitor of T3 action. In this report, we examined further the DNA sequence requirements for {alpha}2 binding to thyroid hormone response elements (TREs) in an attempt to identify response elements that mediate potent inhibition by {alpha}2. Heterodimers of {alpha}2 and retinoid X receptor were found to bind to a subset of TREs (DR4, direct repeats spaced by 4 bp) in which selected flanking and spacer sequences enhanced interactions with the AGGTCA core binding sequence. Despite the optimization of the TRE-binding sites, {alpha}2 remained a weak dominant negative inhibitor of TRE-driven transcription. A promoter interference assay was also developed for testing inhibition by {alpha}2. In these studies, {alpha}2 blocked gene transcription, but it required cotransfected retinoid X receptor, and it was not as potent as unliganded thyroid hormone receptors. These results led to the hypothesis that {alpha}2 might be deficient in interactions with nuclear receptor corepressors. Consistent with this view, {alpha}2 did not silence basal transcription in its native form or when linked to Gal4. {alpha}2 also failed to interact with corepressors (NCoR and SMRT) in both gel shift assays and mammalian two-hybrid assays. We conclude that {alpha}2 is a weak antagonist of thyroid hormone action because it binds weakly to a limited repertoire of response elements, and it does not interact with corepressors. Thus, {alpha}2 may be able to compete with thyroid hormone receptors for binding to a limited group of target sites, but it is not able to actively inhibit transcription.




This article has been cited by other articles:


Home page
 J Mol EndocrinolHome page
T. Tagami, H. Yamamoto, K. Moriyama, K. Sawai, T. Usui, A. Shimatsu, and M. Naruse
The retinoid X receptor binding to the thyroid hormone receptor: relationship with cofactor binding and transcriptional activity
J. Mol. Endocrinol., May 1, 2009; 42(5): 415 - 428.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
T. Tagami, H. Yamamoto, K. Moriyama, K. Sawai, T. Usui, A. Shimatsu, and M. Naruse
A Selective Peroxisome Proliferator-Activated Receptor-{gamma} Modulator, Telmisartan, Binds to the Receptor in a Different Fashion from Thiazolidinediones
Endocrinology, February 1, 2009; 150(2): 862 - 870.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
C.-W. Li, G. K. Dinh, and J. D. Chen
Preferential Physical and Functional Interaction of Pregnane X Receptor with the SMRT{alpha} Isoform
Mol. Pharmacol., February 1, 2009; 75(2): 363 - 373.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
C R Liu, L Y Li, F Shi, X Y Zang, Y M Liu, Y Sun, and B H Kan
Effects of hyper- and hypothyroid on expression of thyroid hormone receptor mRNA in rat myocardium
J. Endocrinol., December 1, 2007; 195(3): 429 - 438.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
C. B. Harvey, J. H. D. Bassett, P. Maruvada, P. M. Yen, and G. R. Williams
The Rat Thyroid Hormone Receptor (TR) {Delta}{beta}3 Displays Cell-, TR Isoform-, and Thyroid Hormone Response Element-Specific Actions
Endocrinology, April 1, 2007; 148(4): 1764 - 1773.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. Mittag, S. Friedrichsen, H. Heuer, S. Polsfuss, T. J. Visser, and K. Bauer
Athyroid Pax8-/- Mice Cannot Be Rescued by the Inactivation of Thyroid Hormone Receptor {alpha}1
Endocrinology, July 1, 2005; 146(7): 3179 - 3184.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
T. E. Sheehan, P. A. Kumar, and D. A. Hood
Tissue-specific regulation of cytochrome c oxidase subunit expression by thyroid hormone
Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E968 - E974.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
B. Z. Doulabi, M. P.-T. Schiphorst, A. Kalsbeek, E. Fliers, O. Bakker, and W. M. Wiersinga
Diurnal Variation in Rat Liver Thyroid Hormone Receptor (TR)-{alpha} Messenger Ribonucleic Acid (mRNA) Is Dependent on the Biological Clock in the Suprachiasmatic Nucleus, whereas Diurnal Variation of TR{beta}1 mRNA Is Modified by Food Intake
Endocrinology, March 1, 2004; 145(3): 1284 - 1289.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
N. Vasudevan, S. Ogawa, and D. Pfaff
Estrogen and Thyroid Hormone Receptor Interactions: Physiological Flexibility by Molecular Specificity
Physiol Rev, October 1, 2002; 82(4): 923 - 944.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
C. Salto, J. M. Kindblom, C. Johansson, Z. Wang, H. Gullberg, K. Nordstrom, A. Mansen, C. Ohlsson, P. Thoren, D. Forrest, et al.
Ablation of TR{alpha}2 and a Concomitant Overexpression of {alpha}1 Yields a Mixed Hypo- and Hyperthyroid Phenotype in Mice
Mol. Endocrinol., December 1, 2001; 15(12): 2115 - 2128.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
L. Ng, A. Rusch, L. L. Amma, K. Nordstrom, L. C. Erway, B. Vennstrom, and D. Forrest
Suppression of the deafness and thyroid dysfunction in Thrb-null mice by an independent mutation in the Thra thyroid hormone receptor {alpha} gene
Hum. Mol. Genet., November 1, 2001; 10(23): 2701 - 2708.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
K.-h. Lin and Y.-h. Wu shen-liang chen
Impaired Interaction of Mutant Thyroid Hormone Receptors Associated with Human Hepatocellular Carcinoma with Transcriptional Coregulators
Endocrinology, February 1, 2001; 142(2): 653 - 662.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
P. E. Macchia, Y. Takeuchi, T. Kawai, K. Cua, K. Gauthier, O. Chassande, H. Seo, Y. Hayashi, J. Samarut, Y. Murata, et al.
Increased sensitivity to thyroid hormone in mice with complete deficiency of thyroid hormone receptor alpha
PNAS, December 14, 2000; (2000) 11306998.
[Abstract] [Full Text]

Home page
 Mol. Cell. Biol.Home page
G. R. Williams
Cloning and Characterization of Two Novel Thyroid Hormone Receptor beta Isoforms
Mol. Cell. Biol., November 15, 2000; 20(22): 8329 - 8342.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
M. L. Hastings, H. A. Ingle, M. A. Lazar, and S. H. Munroe
Post-transcriptional Regulation of Thyroid Hormone Receptor Expression by cis-Acting Sequences and a Naturally Occurring Antisense RNA
J. Biol. Chem., April 6, 2000; 275(15): 11507 - 11513.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
P.-Y. Chien, M. Ito, Y. Park, T. Tagami, B. D. Gehm, and J. L. Jameson
A Fusion Protein of the Estrogen Receptor (ER) and Nuclear Receptor Corepressor (NCoR) Strongly Inhibits Estrogen-Dependent Responses in Breast Cancer Cells
Mol. Endocrinol., December 1, 1999; 13(12): 2122 - 2136.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
C. M. de Arrieta, B. Morte, A. Coloma, and J. Bernal
The Human RC3 Gene Homolog, NRGN Contains a Thyroid Hormone-Responsive Element Located in the First Intron
Endocrinology, January 1, 1999; 140(1): 335 - 343.
[Abstract] [Full Text]

Home page
 Proc. Natl. Acad. Sci. USAHome page
P. E. Macchia, Y. Takeuchi, T. Kawai, K. Cua, K. Gauthier, O. Chassande, H. Seo, Y. Hayashi, J. Samarut, Y. Murata, et al.
Increased sensitivity to thyroid hormone in mice with complete deficiency of thyroid hormone receptor alpha
PNAS, January 2, 2001; 98(1): 349 - 354.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1998 by The Endocrine Society